BioCryst Pharmaceuticals Inc. (BCRX) stands at the threshold of a regulatory decision that could reshape its role in treating hereditary angioedema in children, as the U.S. FDA is scheduled to deliver its decision on December 12, 2025, on the company's New Drug Application for ORLADEYO (berotralstat) Oral Granules, a once-daily formulation designed specifically for pediatric patients aged 2 to 11 years.
Oral Granules Aim to Ease Pediatric Treatment Burden
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.